| Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer S Kamerkar, VS LeBleu, H Sugimoto, S Yang, CF Ruivo, SA Melo, JJ Lee, ... Nature 546 (7659), 498-503, 2017 | 2399 | 2017 |
| Generation and testing of clinical-grade exosomes for pancreatic cancer M Mendt, S Kamerkar, H Sugimoto, KM McAndrews, CC Wu, M Gagea, ... JCI insight 3 (8), 2018 | 722 | 2018 |
| Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity S Kamerkar, C Leng, O Burenkova, SC Jang, C McCoy, K Zhang, ... Science Advances 8 (7), eabj7002, 2022 | 161 | 2022 |
| Toxoplasma on the Brain: Understanding Host‐Pathogen Interactions in Chronic CNS Infection S Kamerkar, PH Davis Journal of parasitology research 2012 (1), 589295, 2012 | 119 | 2012 |
| engineered exosome-mediated STAT6 knockdown in tumor associated macrophages (TAMs) results in potent single agent activity in a hepatocellular carcinoma (HCC) model S Kamerkar, C Leng, O Burenkova, SC Jang, C McCoy, K Zhang, ... Cancer Research 81 (13_Supplement), 1792-1792, 2021 | 4 | 2021 |
| Therapeutic extracellular vesicle production is substantially increased by inhibition of cellular cholesterol biosynthesis S Martin, R McConnell, R Harrison, SC Jang, CL Sia, S Kamerkar, ... Biotechnology and Bioengineering 120 (9), 2685-2699, 2023 | 2 | 2023 |
| Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC) S Kamerkar, C Leng, K Zhang, O Burenkova, SC Jang, S Kasera, T Zi, ... J Immunother Cancer 9 (Suppl 2), A1-A1054, 2021 | 2 | 2021 |
| Methods and compositions for macrophage polarization S Sathyanarayanan, DE Williams, D Burzyn, AT Boutin, S Kamerkar US Patent 11,512,315, 2022 | 1 | 2022 |
| Engineered exosomes efficiently deliver STAT6 antisense oligonucleotides to tumor associated macrophages (TAMs) resulting in potent local and systemic anti-tumor activity S Kamerkar, C Leng, O Burenkova, SC Jang, C McCoy, K Zhang, ... MOLECULAR THERAPY 29 (4), 215-215, 2021 | 1 | 2021 |
| Reprogramming of tumor associated M2 macrophages with antisense oligonucleotide-loaded exosomes results in potent single-agent antitumor activity S Kamerkar, D Burzyn, C Leng, O Burenkova, SC Jang, R Yang, A Boutin, ... Cancer Immunol Res 8 (3), 56, 2020 | 1 | 2020 |
| Extracellular vesicle-aso constructs targeting stat6 D Burzyn, S Kamerkar, AT Boutin, W Broom, S Sathyanarayanan, ... US Patent App. 18/050,017, 2024 | | 2024 |
| Methods for production of msc-derived exosomes E Shpall, R Kalluri, K Rezvani, M Mendt, V LeBleu, S Kamerkar US Patent App. 18/448,254, 2023 | | 2023 |
| Methods and compositions for macrophage polarization S Sathyanarayanan, DE Williams, D Burzyn, AT Boutin, S Kamerkar US Patent App. 18/052,785, 2023 | | 2023 |
| Extracellular vesicle-aso constructs targeting stat6 T Soos, S Kamerkar, SC Jang, K Economides, D Burzyn US Patent App. 18/248,036, 2023 | | 2023 |
| Methods for production of MSC-derived exosomes E Shpall, R Kalluri, K Rezvani, M Mendt, V LeBleu, S Kamerkar US Patent 11,766,402, 2023 | | 2023 |
| Extracellular vesicles with antisense oligonucleotides targeting kras D Burzyn, S Kamerkar, AT Boutin, W Broom, S Sathyanarayanan, ... US Patent App. 17/635,298, 2023 | | 2023 |
| Extracellular vesicle-aso constructs targeting cebp/beta D Burzyn, S Kamerkar, AT Boutin, W Broom, S Sathyanarayanan, ... US Patent App. 17/635,284, 2023 | | 2023 |
| 1345 exoASO-C/EBPβ™: An engineered exosome therapeutic that selectively targets MDSCs and induces potent single-agent anti-tumor activity in checkpoint refractory tumor models S Kamerkar, C Leng, O Burenkova, SC Jang, K Zhang, S Kasera, T Zi, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 1340 BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy K Hurov, L Luus, J Lahdenranta, P Upadhyaya, H Cohen, C Shah, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Exosome-mediated delivery of antisense oligonucleotides targeting C/EBPβ reprograms tumor-associated macrophages and induces potent single agent anti-tumor activity S Kamerkar, C Leng, O Burenkova, SC Jang, K Zhang, Y Liu, W Dahlberg, ... Cancer Research 82 (12), 2022 | | 2022 |